WaveMan · Form 4
Bvf Inc/Il insider trades
> Search tickers & screens ⌘K
LIVE

Bvf Inc/Il insider trades

Bvf Inc/Il has filed 13 Form 4s with the SEC that we hold, for Kymera Therapeutics, Inc. (KYMR) (Director), EPIX (10% owner), Olema Pharmaceuticals, Inc. (OLMA) (Director) and Cullinan Therapeutics, Inc. (CGEM) (10% owner), among 9 companies in all. Across all of them we count 22 purchases worth $26.7M and 9 sales worth $228.0M reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a sale of 8,974,245 shares of PNT worth $111.7M, dated 2023-12-18. The first filing on our record is dated 2022-01-10 and the latest 2025-10-14.

Kymera Therapeutics, Inc. (KYMR)

Director · 3 filings · 10 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-01-27P, purchase reported on Form 437,859$1.5M2022-01-31
2022-01-27P, purchase reported on Form 458,042$2.2M2022-01-31
2022-01-31P, purchase reported on Form 420,085$817.5K2022-01-31
2022-01-31P, purchase reported on Form 414,323$582.9K2022-01-31
2022-05-05P, purchase reported on Form 475,495$1.5M2022-05-09
2022-05-05P, purchase reported on Form 44,066$79.7K2022-05-09
2022-05-05P, purchase reported on Form 470,439$1.4M2022-05-09
2022-05-06P, purchase reported on Form 44,131$79.6K2022-05-09
2022-05-06P, purchase reported on Form 440,659$783.1K2022-05-09
2022-05-06P, purchase reported on Form 455,210$1.1M2022-05-09

EPIX

10% owner · 2 filings · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2025-08-05S, sale reported on Form 479$1492025-08-07
2025-08-05S, sale reported on Form 411$212025-08-07
2025-08-05S, sale reported on Form 466$1242025-08-07

Olema Pharmaceuticals, Inc. (OLMA)

Director · 2 filings · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Cullinan Therapeutics, Inc. (CGEM)

10% owner · 1 filing · 5 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-05-12P, purchase reported on Form 4457,001$4.1M2022-05-16
2022-05-12P, purchase reported on Form 4542,999$4.9M2022-05-16
2022-05-13P, purchase reported on Form 417,744$162.2K2022-05-16
2022-05-13P, purchase reported on Form 438,558$352.4K2022-05-16
2022-05-13P, purchase reported on Form 453,598$489.9K2022-05-16

Eledon Pharmaceuticals, Inc. (ELDN)

10% owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2024-05-09P, purchase reported on Form 41,031,385-2024-05-13
2024-05-09P, purchase reported on Form 4821,121-2024-05-13
2024-05-09P, purchase reported on Form 475,431-2024-05-13

MoonLake Immunotherapeutics (MLTX)

Director, 10% owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

PNT

Reporting owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-12-18S, sale reported on Form 4896,366$11.2M2023-12-20
2023-12-18S, sale reported on Form 47,290,667$90.8M2023-12-20
2023-12-18S, sale reported on Form 48,974,245$111.7M2023-12-20

RAIN (RAIN)

Director, 10% owner · 1 filing · 4 purchases and sales
Trade dateCodeSharesValue as filedFiled
2022-01-06P, purchase reported on Form 461,343$736.1K2022-01-10
2022-01-07P, purchase reported on Form 4255,500$3.1M2022-01-10
2022-01-07P, purchase reported on Form 4226,079$2.7M2022-01-10
2022-01-07P, purchase reported on Form 414,806$177.7K2022-01-10

THRD

Reporting owner · 1 filing · 3 purchases and sales
Trade dateCodeSharesValue as filedFiled
2024-10-29S, sale reported on Form 464,617$924.0K2024-10-31
2024-10-29S, sale reported on Form 4538,420$7.7M2024-10-31
2024-10-29S, sale reported on Form 4396,963$5.7M2024-10-31
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1056807) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms